<DOC>
	<DOCNO>NCT02016755</DOCNO>
	<brief_summary>The purpose study confirm feasibility study procedure tolerability new dose regimen AMG0001 subject Critical Limb Ischemia ( CLI )</brief_summary>
	<brief_title>A Phase IIB Pilot Study Modified Dosage Regimen AMG0001 Subjects With Critical Limb Ischemia</brief_title>
	<detailed_description>The primary objective study : 1 . To confirm feasibility study-related activity tolerability modify dosage regimen AMG0001 CLI 2 . To evaluate safety AMG0001</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Subjects stable CLI ( Severe Rutherford 4 Rutherford 5 ) option revascularization endovascular intervention surgical bypass poor option ( high risk ) revascularization surgery option endovascular intervention Subjects 4090 year either gender sign informed consent Subjects currently take statin antiplatelet agent If female , subject must child bear potential , e.g. , postmenopausal surgically sterile . If male subject reproductive potential , must agree use accepted effective ( barrier ) form birth control start first dose study product continue 12 week last dose study product . Subjects previous medical history myocardial infarction and/or stroke adequate management risk factor prevent secondary occurrence . Subjects ability understand requirement protocol agree return require study visit assessment Subjects whose CLI status unstable ( spontaneous mark improvement mark worsen screen period ) . Subjects may require major amputation ( amputation ankle ) within 4 week Day 0 ( Â± 4 week Day 0 ) . Subjects ulcers exposure tendon , osteomyelitis uncontrolled infection large ulcer great 20 cm2 area ( &gt; 10 cm2 area heel ) . Subjects purely neuropathic venous ulcer . Subjects Rutherford 6 class . Subjects revascularization surgery angioplasty within 3 month , unless procedure fail base anatomy hemodynamic measurement . Subjects diagnosis Buerger 's disease ( Thromboangiitis Obliterans ) . Subjects currently receive immunosuppressive , chemo radiation therapy . Evidence history malignant neoplasm ( clinical , laboratory imaging ) except successfully excise basal cell squamous cell carcinoma , successfully excise early melanoma skin . Subjects , successful tumor resection radiochemotherapy breast cancer 10 year prior inclusion study , recurrence , may enrol study . Subjects , successful tumor resection radiochemotherapy tumor type remission 5 year prior inclusion study , recurrence , may enrol study . A dermatological exam rule skin cancer . Subjects proliferative retinopathy , moderate severe nonproliferative retinopathy , cause ( ETDRS Score &gt; 35 ) , clinically significant macular oedema previous panretinal photocoagulation therapy . Subjects severe renal disease define significant renal dysfunction evidence estimate creatinine clearance &lt; 30 mL/minute ( calculate use Cockcroft Gault formula ) , receive chronic hemodialysis therapy . A Stroke , TIA MI within 3 month entry study . Subjects know liver disease ( e.g. , hepatitis B C cirrhosis liver ) . A subject HIV , AIDS , severe uncontrolled ulcerative colitis Crohn 's disease . Subjects current , uncorrected history alcohol substance abuse . Subjects administer rhPDGF ( e.g , becaplermin ) growth factor locally within one month randomization . Subjects receive another investigational drug within 30 day randomization previously receive gene transfer therapy within 3 year enter study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Vascular Disease</keyword>
	<keyword>CLI</keyword>
	<keyword>Critical Limb Ischemia</keyword>
	<keyword>PAD</keyword>
	<keyword>AnGes</keyword>
	<keyword>HGF Plasmid</keyword>
	<keyword>HGF</keyword>
	<keyword>Hepatocyte Growth Factor Plasmid</keyword>
	<keyword>gene therapy</keyword>
</DOC>